Best Cardiac and Vascular Disorders Companies in Canada
The 72 best Cardiac and Vascular Disorders companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: DalCor.
Ranked: Best Cardiac and Vascular Disorders companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | DalCor Developer of small molecules therapeutics for cardiovascular diseases | $234M | 33 mo ago | 1 | — | — | — | — |
| 2 | Kardium Developer of ablation device for atrial fibrillation 78Funding top 20%Patents top 25%Product top 25%Moat top 26% All 11 signals ▾Fundingtop 20% Patentstop 25% Producttop 25% Moattop 26% Innovationtop 27% Talenttop 28% Growthtop 35% Markettop 42% Techtop 42% Globalbottom 44% Newsbottom 20% Funding: Raised $221M across 5 rounds · 5 rounds over 16 yrs (0.3/yr) Patents: 446 patents matched (strict assignee match) · 131 filings since 2022 vs 180 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $221M | 11 mo ago | 230 | Sam Lichtenstein Co-Founder | — | 444 patents Cardiac electrophysiology mapping and pulsed-field ablation catheter technologies | 1 award |
| 3 | Milestone Pharmaceuticals Provider of small molecule based drug development for treating cardio vascular conditions | $174M | 38 mo ago | 39 | — | 3 signals ▼57% Regulatory · Earnings | 115 patents Water‑soluble short‑acting phenylalkylamine calcium‑channel blocker salts for drug formulation | 1 partnership |
| 4 | Resverlogix Provider of small molecule BET-inhibitors for CV disease for treating diabetes | $129M | 68 mo ago | 19 | — | 5 signals ▼44% Leadership · Regulatory · Earnings | 303 patents Epigenetic BET bromodomain inhibition combined with SGLT2 inhibition for cardiovascular and renal therapies | — |
| 5 | Neovasc Developer of devices to treat cardiovascular conditions | $119M | 51 mo ago | 63 | — | — | 18 patents Transcatheter mitral valve replacement devices and delivery system technologies | — |
| 6 | Flosonics Medical Developer of non-invasive hemodynamic monitoring devices 48Funding top 29%Moat top 32%Product top 35%Patents top 39% All 9 signals ▾Fundingtop 29% Moattop 32% Producttop 35% Patentstop 39% Innovationtop 42% Techtop 44% Globalbottom 43% Marketbottom 39% Newsbottom 22% Funding: Raised $39.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 22 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $39M | 15 mo ago | 38 | — | — | 22 patents Wearable ultrasound fluid monitoring patches and dynamically controllable patient fluid therapy devices. | 2 job openings · 2 awards |
| 7 | Conavi A catheter-based ultrasound system for cardiac imaging 48Funding top 24%Growth top 38%News top 38%Partners top 40% All 9 signals ▾Fundingtop 24% Growthtop 38% Newstop 38% Partnerstop 40% Moattop 48% Talentbottom 49% Marketbottom 48% Techbottom 41% Globalbottom 29% Funding: Raised $27.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Growth: 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $28M | 5 mo ago | 76 | Aman Thind Co-founder and Chief Technology Officer | 14 signals ▼18% Regulatory · Announcements · Earnings | — | 1 award |
| 8 | Acorn Cardiovascular Mesh for heart failure | $26M | 192 mo ago | — | Steven M. Anderson CEO | — | — | — |
| 9 | Puzzle Medical Devices Developer of a minimally invasive heart pump 57Patents top 24%Talent top 28%Innovation top 31%Moat top 31% All 9 signals ▾Patentstop 24% Talenttop 28% Innovationtop 31% Moattop 31% Growthtop 35% Fundingtop 37% Techbottom 48% Globalbottom 42% Marketbottom 35% Patents: 64 patents matched (strict assignee match) · 50 filings since 2022 vs 14 in 2017-21 Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $25M | 15 mo ago | 24 | Gabriel Georges Co-Founder | — | 64 patents Implantable modular fluid‑flow control and pump systems for therapeutic drug delivery | 3 job openings |
| 10 | Thryv Therapeutics Provider of precision medicines for cardiovascular and related diseases | $24M | 36 mo ago | 22 | Paul Truex CEO | — | 17 patents Small-molecule SGK-1 kinase inhibitors for cancer treatment | — |
| 11 | Soundbite Medical Shockwave device to treat chronic total occlusions in the coronary and peripheral vasculature | $22M | 98 mo ago | 18 | Louis-Philippe Riel Co-Founder and Director Disposables & Systems | — | — | — |
| 12 | MeaCor Developing a transcatheter heart valve repair device to treat valvular disease | $15M | 25 mo ago | 2 | — | — | 3 patents Provides minimally invasive surgical instrument support and helical anchor deployment systems. | — |
| 13 | OpSens Manufacturer of optical sensors | $15M | 60 mo ago | 18 | Christopher Simon CEO | — | 140 patents Intravascular pressure sensing for cardiac/hemodynamic monitoring and structural heart interventions. | — |
| 14 | Phraxis Vascular access device for hemodialysis | $14M | 30 mo ago | 4 | Alex Yevzlin Co-Founder | — | — | — |
| 15 | Data Sciences Int. Wireless implantable telemetry devices and data analytic IT solutions | $12M | 292 mo ago | 180 | — | — | — | 1 launch |
| 16 | CellAegis Devices A non-invasive, automated device for Chronic Remote Ischemic Conditioning | $10M | 111 mo ago | 5 | — | — | 50 patents Remote ischemic conditioning devices for therapeutic blood flow modulation | — |
| 17 | Matrizyme Pharma Collagenase formulation for chronic total occlusions | $10M | 155 mo ago | — | Bradley Strauss Founder & Chairman | — | — | — |
| 18 | VentriPoint Heart analysis system 62News top 18%Product top 24%Growth top 25%Partners top 32% All 10 signals ▾Newstop 18% Producttop 24% Growthtop 25% Partnerstop 32% Fundingtop 36% Globaltop 37% Techtop 44% Innovationtop 47% Moattop 48% Marketbottom 45% News: 9 BI events in 12 mo (of 46 tracked, 7 types) · +350% YoY Product: 1 product launch event in 12 mo · 12 distinct product lines rank vs industry peers · Fliar Intelligence Index 62/100 | $9M | 16 mo ago | — | — | 9 signals ▲350% Announcements · Funding · Regulatory | — | — |
| 19 | Cardiol Therapeutics Developer of anti-inflammatory therapies for heart disease 53News top 24%Growth top 25%Patents top 31%Moat top 32% All 11 signals ▾Newstop 24% Growthtop 25% Patentstop 31% Moattop 32% Innovationtop 34% Fundingtop 37% Talentbottom 49% Techbottom 41% Globalbottom 36% Partnersbottom 35% Marketbottom 33% News: 16 BI events in 12 mo (of 39 tracked, 6 types) · +129% YoY Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $9M | 8 mo ago | 17 | David Elsley President & CEO/Founder | 16 signals ▲129% Funding · Earnings · Contracts | 55 patents Cannabinoid-based cardiac therapies and polymeric delivery systems for pericarditis and heart failure | 1 award |
| 20 | Pivotal Therapeutics Canadian, commercial-stage biopharma developing highly-purified prescription Omega 3 Therapy for CVD | $8M | 147 mo ago | — | George Jackowski Co-Founder & CSO | — | 44 patents Omega‑3 fatty acid therapeutics and diagnostics for cardiovascular risk reduction and plaque stabilization | — |
| 21 | Mannin Research Developer of therapeutics for vascular diseases | $8M | 79 mo ago | 2 | — | — | — | — |
| 22 | Paradox Immunotherapeutics Developer of immunotherapeutics for the treatment of rare diseases | $7M | 15 mo ago | 9 | Yulong Sun Co-Founder | — | 5 patents Therapeutic monoclonal antibodies targeting conformational epitopes of lambda immunoglobulin light chains | — |
| 23 | Liphorus Pharmaceuticals Small molecule targeting PCSK9 for the treatment of hypercholesterolemia | $6M | 139 mo ago | — | Andrew Jennings Co-Founder | — | — | — |
| 24 | Fluid Biomed Developer of medical device to treat brain aneurysms | $6M | 18 mo ago | 11 | John Wong Co-Founder & CEO | — | 9 patents Bioabsorbable flow‑diverting scaffolds and compression systems for endovascular interventions | — |
| 25 | Synex Medical Developer of non-invasive health monitoring technology using magnetic resonance spectroscopy | $5M | 67 mo ago | 24 | Ben Nashman Founder & CEO | — | 30 patents Patents concentrated in health & consumer products | — |
| 26 | CardioComm Solutions Provides software for electrocardiogram (“ECG”) management and reporting software | $4M | 144 mo ago | 23 | Etienne Grima CEO | 5 signals Announcements · Funding · Regulatory | 2 patents Unlocking and managing OTC biosignal recording devices for health monitoring | — |
| 27 | Total Flow Medical Developer of medical devices for cardiopulmonary bypass | $4M | 49 mo ago | 5 | Luke Harris Co-founder and Inventor | — | — | — |
| 28 | LGTmedical Smartphone attached pulse oximeter | $2M | 147 mo ago | 7 | Tom Walker President & CEO | — | — | — |
| 29 | CardioGenics Develops ultra-sensitive analyzers and immunoassay tests for In-vitro diagnosis | $2M | 184 mo ago | 4 | — | — | 18 patents Point‑of‑care diagnostic devices and reagents for chemiluminescent immunoassays | — |
| 30 | CVR Medical Diagnostic technology to assess the risk of Ischemic stroke | $2M | 54 mo ago | — | Peter Bakema CEO & President | — | — | — |
| 31 | Hemostemix Developer of autologous cell therapy for the treatment of ischemic diseases | $1M | 17 mo ago | 13 | — | — | — | — |
| 32 | Vesalius Cardiovascular Biomedical devices for the treatment of mitral valve regurgitation | $1M | 10 mo ago | 12 | Peter Skarsgard Co-Founder | — | 52 patents Minimally invasive mitral valve repair devices and tissue anchoring systems | — |
| 33 | Event Cardio Group Ambulatory portable cardiac monitoring devices | $295K | 130 mo ago | 11 | John Bentivoglio CEO & President | — | 3 patents Wireless cardiac event recorders for remote heart rhythm monitoring | — |
| 34 | HelpWear Wearable device for cardiac monitoring | $120K | 108 mo ago | 19 | — | — | 12 patents Wearable dry‑electrode ECG monitoring devices for single‑arm cardiac sensing | — |
Top 12 Cardiac and Vascular Disorders companies in Canada
#1
Series C · Burnaby, British Columbia · founded 2007 · 230 employees$221.4Mraised▾
Kardium is developing the Globe mapping and ablation system. It's an investigational medical device, used in the diagnosis and treatment of atrial fibrillation. It provides mapping, stimulation, and RF ablation of cardiac tissue.
- Jul 2025Series C$250M
- Jun 2024Series B$104M
- Dec 2020Series B$116.3M
- Feb 2019Series A—
#2
Public · Toronto, Ontario · founded 2007 · 76 employees$27.7Mraised▾
A catheter-based ultrasound system for cardiac imaging. The company has developed, Foresight ICE System, a catheter-based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter's tip.
- Jan 2026Post IPO$700K
- Apr 2025Post IPO$15.5M
- Oct 2024Series B$7.7M
- Dec 2021Series B$20M
#3
Public · Oakville, Ontario · founded 2017 · 17 employees$8.9Mraised▾
Developer of anti-inflammatory therapies for heart disease. It focuses on the research and clinical development of treatments targeting inflammation and fibrosis in conditions like pericarditis, myocarditis, and heart failure. The company's pipeline includes drug candidates currently in clinical trials. Its approach involves understanding the role of inflammation and fibrosis in cardiac diseases to develop therapies promoting healing.
- Oct 2025Post IPO$11M
- Mar 2021Post IPO$10M
- Dec 2020Post IPO$829.1K
- Jan 2019Post IPO$3.7M
#4
Series C · Greater Sudbury, Ontario · founded 2015 · 38 employees$39Mraised▾
Flosonics Medical is a developer of non-invasive sensors for the management of critically ill patients, performing continuous monitoring of arterial flow with automatic artery detection. The company develops products for fluid responsiveness detection in the ICU, E.D, and operating room. The company's smart-bandage product, FloPatch, is designed to address the clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit. The patch is disposable and is enabled with ultrasound technology.
- Mar 2025Venture Debt$5.2M
- May 2024Series C$20M
- Feb 2021Series A$14M
- Sep 2019Grant (prize money)—
#5
Series B · Montreal, Montreal · founded 2018 · 24 employees$25Mraised▾
Developer of a minimally invasive heart pump. The company has developed a minimally invasive long-term hemodynamic transcatheter pump heart for treating patients with end-stage heart failure.
- Mar 2025Series B$5.5M
- Jan 2025Series B$30M
- Feb 2023Series A$25M
- Jan 2022Seed—
#6
Public · Toronto, Ontario · founded 2005$9.1Mraised▾
Ventripoint Diagnostics is a medical device company that develops and commercializes its diagnostic tools to monitor patients with heart disease. By using images produced from existing medical imaging systems, the Ventripoint Medical System (VMS), an FDA cleared device, generates heart volumetric measurements and a three-dimensional (3D) model. Its solution produces heart information by processing information received from existing medical imaging equipment with its patented and own methods incorporating Knowledge-Based Reconstruction (KBR) algorithms and own cardiac databases. Its KBR method allows for the creation of a 3D model of the right and/or left ventricle using images generated from existing two-dimensional imaging equipment.
- Feb 2025Post IPO$60.7K
- Jan 2025Post IPO$117.3K
- Dec 2024Post IPO$239.5K
- Nov 2024Post IPO$13.8K
#7
Series A · Toronto, Ontario · founded 2019 · 9 employees$7Mraised▾
Developer of immunotherapeutics for the treatment of rare diseases. The company has a drug design platform to develop monoclonal antibody (mAb) treatment for protein misfolding diseases. The drug pipeline inlcudes LX-96 for heart failure, KX-99 for ALECT2 amyloidosis, and NX-86 for neurodegenerative diseases.
- Feb 2025Series A$7M
#8
Seed · Vancouver, British Columbia · founded 2016 · 12 employees$1Mraised▾
Vesalius Cardiovascular is developing biomedical devices for the treatment of mitral valve regurgitation. The company is developing Calla-TC3 and LAD, for the treatment of degenerative MR (due to mitral valve prolapse) and functional MR (due to cardiomyopathy). The devices that can be introduced percutaneously into the heart.
- Aug 2025Seed$50.3K
- Dec 2024Seed$689.9K
- Nov 2024Seed$107K
- Sep 2023Seed$37.8K
#9
Series D · Montreal, Montreal · founded 2015 · 1 employees$233.9Mraised▾
DalCor Pharmaceuticals develops small molecule therapeutics for cardiovascular diseases. Its lead candidate Dalcetrapib is a cholesterol ester transfer protein (CETP) inhibitor to treat the cardiovascular disease risk caused by the mutations in the ADCY9 gene. Dalcetrapib is currently in phase III trials for the treatment of a genetic subpopulation of patients suffering from Acute Coronary Syndrome (ACS).
- Sep 2023Series D$80M
- May 2020Series B$3.9M
- May 2020Conventional Debt—
- Apr 2016Series B$100M
#10
Series A · Calgary, Alberta · founded 2012 · 11 employees$5.5Mraised▾
Developer of medical device to treat brain aneurysms. The company has developed a hybrid polymer-metal flow-diverting stent to cure brain aneurysms. Also, its proprietary stent delivery system is used to navigate to bypass the aneurysm under angiographic guidance.
- Dec 2024Series A$27M
- Aug 2021Seed$4.7M
- Feb 2020Seed$846.7K
#11
Public · Montreal, Montreal · founded 2005 · 39 employees$174.5Mraised▾
Provider of small molecule based drug development for treating cardio vascular conditions. The company's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina. The product is being developed as a nasal spray to provide for rapid systemic drug delivery.
- Mar 2023Post IPO$125M
- Jul 2020Post IPO$18.6M
- Oct 2018Series D$80M
- Aug 2017Series C$55M
#12
Public · Calgary, Alberta · founded 2006 · 13 employees$1.3Mraised▾
Developer of autologous cell therapy for the treatment of ischemic diseases. The lead product ACP-01 is an autologous cell therapy for the treatment of critical limb ischemia which is characterised by chronic, inadequate blood flow to limbs, resulting in tissue loss and gangrene.
- Jan 2025Post IPO$284.4K
- Sep 2023Post IPO$240.9K
- Jun 2023Post IPO$403.5K
- Jan 2020Post IPO$2.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.